Latest Period
Q2 2026
Security Snapshot
Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) Institutional Ownership
CUSIP: G52694109
13F Institutional Holders and Ownership History from Q2 2024 to Q2 2026
Institutions Reporting
266
Shares (Excl. Options)
46,937,572
Price
$63.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- KNSA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 46,937,572
- Total 13F value
- $2,992,857,161
- Portfolio coverage rank
- 0%
- Share change
- +1,670,424
- Value change
- +$125,603,137
- Number of holders
- 266
- Shares outstanding
- 46,087,073
- SEC-reported price per share
- $80.92
- Insider filing price
- $80.92
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KNSA - Kiniksa Pharmaceuticals International, plc - Common Stock is tracked under CUSIP G52694109.
- 266 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 226 to 266 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,181,913,275 to $2,992,857,161.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 266 institutions filings for Q2 2026.
Security key
G52694109
Latest holder period
Q2 2026
13F holders
266
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
KNSA full holder history
Kiniksa Pharmaceuticals International, plc SEC filings
Kiniksa Pharmaceuticals International, plc company facts
Kiniksa Pharmaceuticals International, plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G52694109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
KNSA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +38% | $326,692,012 | +$93,051,943 | 6,787,700 | +40% | FMR LLC | 31 Mar 2026 |
| Rubric Capital Management LP | 7.4% | -21% | $139,836,713 | -$24,414,238 | 3,328,653 | -15% | Rubric Capital Management LP | 31 Dec 2025 |
| BAKER BROS. ADVISORS LP | 7% | $140,056,330 | 3,253,341 | Julian C. Baker | 21 May 2026 | |||
| VANGUARD GROUP INC | 7% | $118,941,532 | 3,063,135 | The Vanguard Group | 30 Sep 2025 | |||
| BlackRock, Inc. | 5.5% | +450% | $162,099,757 | +$135,359,000 | 2,534,789 | +506% | BlackRock, Inc. | 30 Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 5.2% | $46,556,874 | 2,178,609 | TANG CAPITAL MANAGEMENT, LLC | 28 Mar 2025 |
As of 30 Jun 2026, 266 institutional investors reported holding 46,937,572 shares of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA). This represents 102% of the company’s total 46,087,073 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
75%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 6,971,361 | +2.2% | 0.02% | $445,818,527 |
| Rubric Capital Management LP | 8.7% | 3,999,800 | +6.7% | 2.3% | $255,787,210 |
| BAKER BROS. ADVISORS LP | 6.2% | 2,834,643 | +0.3% | 0.91% | $181,275,420 |
| BlackRock, Inc. | 5.9% | 2,739,615 | +463% | 0% | $175,198,378 |
| TANG CAPITAL MANAGEMENT LLC | 4.9% | 2,259,889 | 0% | 6.6% | $144,519,902 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.1% | 1,911,335 | +8.2% | 0.01% | $122,229,873 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3% | 1,360,840 | +2.1% | 0% | $87,025,718 |
| MORGAN STANLEY | 2.2% | 1,011,143 | +1.3% | 0% | $64,662,626 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.1% | 957,514 | +7.3% | 0.03% | $61,233,020 |
| Spruce Street Capital LP | 2% | 918,070 | +21% | 12% | $58,710,577 |
| DIMENSIONAL FUND ADVISORS LP | 1.9% | 874,786 | +7.7% | 0.01% | $55,937,333 |
| Invesco Ltd. | 1.7% | 772,806 | +2694% | 0% | $49,420,945 |
| Driehaus Capital Management LLC | 1.6% | 718,199 | +17% | 0.27% | $45,928,826 |
| STATE STREET CORP | 1.5% | 704,194 | +819% | 0% | $45,033,206 |
| ACADIAN ASSET MANAGEMENT LLC | 1.5% | 679,083 | -49% | 0.05% | $43,409,000 |
| Point72 Asset Management, L.P. | 1.4% | 659,493 | +2.9% | 0.06% | $42,174,577 |
| RICE HALL JAMES & ASSOCIATES, LLC | 1.4% | 624,928 | +2.7% | 1.9% | $39,964,146 |
| Pictet Asset Management Holding SA | 1.3% | 608,650 | -2.3% | 0.04% | $38,923,168 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 604,180 | +1263% | 0% | $38,633,635 |
| Jupiter Topco LLC | 1.3% | 586,177 | 0% | 0.02% | $37,472,380 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.2% | 572,598 | -12% | 0.07% | $36,617,642 |
| D. E. Shaw & Co., Inc. | 1.2% | 569,756 | -41% | 0.02% | $36,435,896 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 561,480 | +33% | 0.03% | $35,906,646 |
| ALLIANCEBERNSTEIN L.P. | 1.2% | 556,151 | -7.1% | 0.01% | $26,778,671 |
| VICTORY CAPITAL MANAGEMENT INC | 1.1% | 504,853 | -0.33% | 0.02% | $32,285,350 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Latest
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 46,937,572 | $2,992,857,161 | +$125,603,137 | $63.95 | 266 |
| 2026 Q1 | 45,404,596 | $2,181,913,275 | +$142,639,064 | $48.15 | 226 |
| 2025 Q4 | 42,953,248 | $1,771,666,340 | +$79,894,259 | $41.25 | 222 |
| 2025 Q3 | 40,790,628 | $1,583,711,476 | +$42,923,169 | $38.83 | 200 |
| 2025 Q2 | 39,765,765 | $1,100,293,484 | +$3,474,538 | $27.67 | 186 |
| 2025 Q1 | 39,936,950 | $887,052,494 | +$25,344,007 | $22.21 | 173 |
| 2024 Q4 | 38,910,834 | $769,756,202 | -$20,642,445 | $19.78 | 156 |
| 2024 Q3 | 39,503,444 | $987,347,556 | +$124,891,730 | $24.99 | 172 |
| 2024 Q2 | 35,248,812 | $658,014,093 | +$655,780,340 | $18.67 | 126 |